Aeglea BioTherapeutics (AGLE) News Today → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free AGLE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineNorthwest Biotherapeutics Stock (OTC:NWBO), Analyst Ratings, Price Targets, Predictionsbenzinga.com - February 21 at 7:08 PMBridge Biotherapeutics Inc.wsj.com - January 30 at 8:34 PMSpyre Therapeutics Announces $180 Million Private Placementfinance.yahoo.com - December 7 at 8:14 PMAeglea Biotherapeutics announces name change to Spyre Therapeuticsmsn.com - November 27 at 10:33 AMAeglea BioTherapeutics Changes Name To Spyre Therapeutics; To Begin Trading Under Symbol SYREmarkets.businessinsider.com - November 27 at 10:33 AMAeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBDfinance.yahoo.com - November 27 at 10:33 AMAeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 9 at 6:41 PMAeglea BioTherapeutics to Participate in Upcoming November Investor Conferencesfinance.yahoo.com - October 30 at 10:40 PMAeglea BioTherapeutics (AGLE) Price Target Increased by 2435.71% to 18.11msn.com - October 5 at 8:47 PMAeglea BioTherapeutics Announces Grants of Inducement Awardsfinance.yahoo.com - October 2 at 10:47 PMAeglea BioTherapeutics to Participate in Upcoming September Conferencefinance.yahoo.com - September 14 at 6:59 PMAeglea Biotherapeutics (AGLE) Gets a Buy from Stifel Nicolausmarkets.businessinsider.com - September 14 at 1:49 AMAeglea BioTherapeutics (NASDAQ:AGLE) Cut to Sell at StockNews.commarketbeat.com - September 8 at 9:17 PMAeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Announces Reverse Stock Splitfinanznachrichten.de - September 8 at 6:06 PMmarketbeat.com - September 8 at 9:38 AMAeglea BioTherapeutics Announces Reverse Stock Splitfinance.yahoo.com - September 7 at 9:21 AMAeglea BioTherapeutics appoints Burrows as CFO, King-Jones as CLOseekingalpha.com - September 5 at 5:21 PMAeglea BioTherapeutics Appoints Scott Burrows As Chief Financial Officermarkets.businessinsider.com - September 5 at 5:21 PMAeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jonesfinance.yahoo.com - September 5 at 7:36 AMWells Fargo Maintains Aeglea BioTherapeutics (AGLE) Equal-Weight Recommendationmsn.com - August 16 at 3:59 PMAeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Resultsfinanznachrichten.de - August 11 at 7:54 PMAeglea BioTherapeutics Reports Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 11 at 7:54 PMAeglea BioTherapeutics (NASDAQ: AGLE)fool.com - August 10 at 10:36 AMAeglea BioTherapeutics (AGLE) Price Target Decreased by 54.54% to 1.45msn.com - August 3 at 8:06 PMAeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharmafinance.yahoo.com - July 27 at 11:36 AMAeglea initiated with Buy at Stifel citing potential in IBD spaceseekingalpha.com - July 25 at 9:35 PMStifel Initiates Coverage of Aeglea BioTherapeutics (AGLE) with Buy Recommendationmsn.com - July 25 at 9:35 PMAeglea Biotherapeutics (AGLE) Initiated with a Buy at Stifel Nicolausmarkets.businessinsider.com - July 25 at 8:16 AMFunding wrap: Former Dell Med dean raises $30Mbizjournals.com - June 26 at 2:07 PMAeglea BioTherapeutics Announces Grant of Inducement Awardsfinance.yahoo.com - June 23 at 6:39 PMM&A Wrap: Aeglea grabs another biotech co., $210M; Wealth manager acquiredbizjournals.com - June 23 at 1:39 PMAeglea BioTherapeutics stock skyrockets as it boosts inflammatory bowel disease portfolio with Spyre Therapeutics acquisitionproactiveinvestors.com - June 22 at 3:53 PMWhy Is Aeglea BioTherapeutics (AGLE) Stock Up 392% Today?investorplace.com - June 22 at 12:02 PMAeglea BioTherapeutics Shares Spike After Merger, New Fundingmarketwatch.com - June 22 at 10:53 AMAeglea BioTherapeutics Stock Surges Over 400% Today - What's Going Onbenzinga.com - June 22 at 10:53 AMAeglea BioTherapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lagsfinance.yahoo.com - May 13 at 10:12 AMRecap: Aeglea BioTherapeutics Q1 Earningsmsn.com - May 12 at 9:41 AM10-Q: AEGLEA BIOTHERAPEUTICS, INC.marketwatch.com - May 12 at 4:28 AMAeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue Estimatesfinance.yahoo.com - May 11 at 1:25 PMAeglea BioTherapeutics, Inc.: Aeglea BioTherapeutics Reports First Quarter 2023 Financial Resultsfinanznachrichten.de - May 11 at 8:25 AMAeglea BioTherapeutics Reports First Quarter 2023 Financial Resultsfinance.yahoo.com - May 11 at 8:25 AMLifeSci Capital Downgrades Aeglea BioTherapeutics (AGLE)msn.com - April 13 at 9:06 PMJonesTrading Downgrades Aeglea BioTherapeutics (AGLE)msn.com - April 13 at 9:06 PMAeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Failsmsn.com - April 13 at 11:04 AMWhy Are Aeglea BioTherapeutics Shares Sinking Today?msn.com - April 12 at 6:19 PMJonesTrading Sticks to Its Hold Rating for Aeglea Biotherapeutics (AGLE)markets.businessinsider.com - April 12 at 1:17 PMAeglea slumps ~25% as trial results trigger strategic options, workforce reductionmsn.com - April 12 at 8:16 AMAeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternativesfinance.yahoo.com - April 12 at 8:16 AMAeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - March 17 at 6:59 PMAeglea BioTherapeutics's Return On Capital Employed Insightsmsn.com - March 7 at 10:52 PM Get Aeglea BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide AGLE Media Mentions By Week AGLE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGLE News Sentiment▼0.000.33▲Average Medical News Sentiment AGLE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGLE Articles This Week▼01▲AGLE Articles Average Week Get Aeglea BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: DARE News Today APLM News Today JAGX News Today CALC News Today GANX News Today NXTC News Today XLO News Today SCYX News Today AADI News Today BOLT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AGLE) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeglea BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
